$1.22
+0.05 (+4.27%)
Open$1.18
Previous Close$1.17
Day High$1.24
Day Low$1.15
52W High$2.40
52W Low$1.00
Volume—
Avg Volume2.50M
Market Cap29.44M
P/E Ratio—
EPS$-1.84
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+3,748.4% upside
Current
$1.22
$1.22
Target
$46.95
$46.95
$33.28
$46.95 avg
$64.49
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 47.89M | 42.94M | 46.10M |
| Net Income | 949.8K | 770.7K | 699.4K |
| Profit Margin | 2.0% | 1.8% | 1.5% |
| EBITDA | 1.44M | 1.43M | 1.37M |
| Free Cash Flow | 717.1K | 500.4K | 604.2K |
| Rev Growth | -0.9% | +8.9% | +4.5% |
| Debt/Equity | 0.33 | 0.39 | 0.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |